Roche breast cancer trial misses endpoint
The Roche Group announced on 9 March that one of five trials of a Phase 3 development programme for giredestrant, a small molecule drug for breast cancer, failed to demonstrate progression-free survival. The Phase 3 trial, persevERA, was being conducted globally in 992 patients with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Giredestrant was being tested as a first-line therapy in combination with palbociclip (Ibrance), an approved cyclin-dependent kinase (CDK) 4/6 inhibitor.
